November 4, 2024Krystal Biotech, Inc. beats earnings expectations. Reported EPS is $0.909, expectations were $0.9. Operator: Thank you for standing by and welcome to Krystal Biotech's Third Quarter ...

Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET. Company Participants. Stéphane Paquette - VP, Corporate Development Krish Krishn ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug ...

ADRX-0405 is a novel antibody-drug conjugate targeting STEAP1, and a phase 1a/b study will investigate the agent for the ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

with efficient editing and very low off-target activities, which was also published in Nature Biotechnology 2022, laying out the technical foundation of the CRISPR/Cas13 system for future clinical ...

Lyell Immunopharma, Inc.'s strong financials, innovative CAR T-cell therapies, and strategic acquisitions position it for ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...

Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the ...

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third ...

( MENAFN - GlobeNewsWire - Nasdaq) INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient's body to target CD20-expressing ...